May 13, 2024 Numinus Wellness inc. Sponsored Post

Mental Health Has Never Seen This Kind Of Progress Before

One biotech company, Numinus Wellness Inc. (TSX:NUMI) positions itself in a new industry backed by Kevin O’Leary to transform the way we treat mental health

 

When Canada legalized a certain controversial mental health treatment, many people were shocked12...

It could get rid of antidepressants.

It could eliminate the need for traditional therapy.

There may no longer be months of "talking about your feelings" with a counsellor.

What's REALLY great is you could relieve depression with 4 TIMES more efficacy than old-school medication.3

It's safer, cheaper, and has fewer intense side effects.

Many veterans in case studies have quickly gotten over PTSD with this exact method.45

And one recent success story is Eric Bjarnason, a retired fireman, who described how he "purged" himself of depression after only one session.6

Given this treatment is filling the big mental health gap left by Big Pharma, it’s obvious why it's estimated to be…

"A New $100 Billion Market!”7

What’s this breakthrough the Canadian government is backing?

Surprisingly, it’s the use of hallucinogens in therapy.

Yes, we’re talking about "medications" like magic mushrooms (psilocybin), acid, and hallucinogens —

The kind people usually associate with “hippies” and party animals.

But with hallucinogens now proven by science to be the next Holy Grail in mental health…

… there has been a strong legal push to incorporate them into clinical settings, especially in Canada and the U.S. states of New York and California.89

And taking center stage in this $100 billion revolution is a biotech company called Numinus Wellness Inc. (TSX:NUMI).

It’s the first publicly-traded company to receive a license from Health Canada for the cultivation and research of psilocybin mushrooms, with…

    • 5 approved treatment clinic (1 in Vancouver, 1 in Toronto, 3 in Montreal, and likely 6 more to open in 2022)
    • 2 research facilities staffed with scientists, doctors, and other health professionals
    • Plans to expand into the U.S.

Turns out, there's truth in street-claims about hallucinogens' healing power after all…

Breaking News

Why Numinus Wellness Inc. (TSX:NUMI). Could Be The Next “Biotech Behemoth” With Significant Potential!

If you're skeptical about the idea of hallucinogens, then get this:

There's a giant non-profit called Multidisciplinary Association For Hallucinogenics Studies (MAPS).

It was founded in 1986 to discover MJJ's and hallucinogens' medical benefits, and it has raised over $130 million for their research and education!10

As you may know, organizations like this have been responsible for the legal progression of cannabis for decades.

Obviously, MMJ stocks are now beyond speculation, as many of them are heading for the moon.

And investors who thought "substances can never be legal or medicine" are now left behind.

History Could Be About To Repeat Itself With Hallucinogenics

…given MAPS, one of the most prominent organizations in the space, beginning to sponsor one of Numinus Wellness’s clinical trials on January 19th, 2022.11

The result is the company can now – besides psilocybin – enroll people in molly-assisted psychotherapy for PTSD, which is unprecedented!

But saying that mind-altering medicine stocks will be as big as cannabis undermines the potential of this "mental health revolution." -- take a look at this quote from CNBC:
12

Yes, even “Mr. Wonderful,” the highly-picky investor, thinks hallucinogens are bigger than the cannabis wave that came before, which is why he invested in MindMed and Compass Pathways13, two other hallucinogenic companies...

... and why PayPal billionaire Peter Thiel backed ATAI Life sciences, a similar firm.14

Clearly, investors are willing to put their hard-earned cash into this promising field.

And the good news is that putting Numinus on your watchlist could be equally profitable as when Kevin O'Leary and Peter Thiel invested in other mind-altering medicine companies.

It’s because Numinus Wellness Inc. (TSX:NUMI) has a strong scientific background, relationships with regulators, treatment services, and state-of-the-art labs for research and testing, which have helped the company record a 245% year-over-year revenue growth as of Q1 of 2022!15

So, it makes sense to hold this undervalued stock than its peers' before the word spreads. Here’s why more investors could be attracted to Numinus:

Unique Two-Pronged Business Strategy

Already, Numinus Wellness Inc. (TSX:NUMI) has paved the way for the hallucinogenics industry through several significant firsts thanks to its powerful, multi-pronged business strategy that includes:

1. NUMINUS BIOSCIENCE:

It is the first public company to complete a legal harvest of psilocybe mushrooms (or ‘magic mushrooms’) and is among the first licensed to handle a variety of hallucinogenic substances such as acid, mescaline, N,N-Dimethyltryptamine, N-Methyl-3,4, methylenedioxyamphetamine (molly), psilocin, and psilocybin.

Numinus Wellness Inc. (TSX:NUMI) received amendments on March 4, 2021, that bolstered its federal license, allowing the company to possess, formulate, produce, assemble, sell, import-export, deliver and distribute hallucinogenics.16

These new license amendments not only place the company at the forefront of global hallucinogenics research, but it also establishes Numinus’s supplier status for mushroom spores and tissue culture to other licensed dealers, as well as doubled the company’s admissible psilocybin production to 1 kilogram.

On March 9, 2021, The Numinus Wellness Inc. (TSX:NUMI) announced plans on March 9 to expand its existing hallucinogenics research laboratory by 7,500 square feet.

This includes equipping the lab with $1.2 million worth of next-generation analytical equipment such as the Orbitrap Exploris 120 Mass Spectrometer, a high-resolution mass spectrometry instrument.

Numinus Wellness (TSX:NUMI) has continued to see positive results from its Health Canada licensed laboratory, and is making huge strides already in 2022.

On January 14th, 2022, the company applied to Health Canada for a Phase 1 study, called HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01.17

This is significant because, by creating a "mushroom extract" that is shelf–stable, has proven bioavailability, and can be packaged easily, Numinus Wellness Inc. (TSX:NUMI) can likely expand the scalability of its treatment clinics, and advance its product development pipeline so it can eventually reach mass retailers.

Imagine the first generation of commercial mushrooms on shelves everywhere, just like you see packaged cannabis of all types in stores in Canada and American states where it is legal.

Numinus has made notable progress in treating PTSD through compassionate access trials for hallucinogenics-assisted therapy as well as in advancing a compassionate access trial for Psilocybin-Research Intervention with Motivational Enhancement (PRIME) to treat substance use disorders.

The hallucinogenics-assisted therapy for PTSD, which is in collaboration with MAPS, is the first of its kind in Canada.

[BONUS-POPUP id="1"]
MAPS is the leading developer of molly-assisted therapy training programs, treatment protocols, and research. When Health Canada approved the MAPS-sponsored open-label safety study evaluating molly-assisted therapy for PTSD, it gave both companies a huge boost.18

MAPS founder Rick Doblin speculates that hallucinogenics and hallucinogenic-assisted therapies will penetrate mainstream culture by 2070,19 but with the progress MAPS is making now, and getting a “No Objection” letter from Health Canada, it seems like that timeline needs to be pushed up.

MAPS leads the pack of non-profits in the hallucinogenic space, and it has a clear R&D strategy to make it happen.

In February 2021, the company advanced the trial and transitioned into the pre-implementation stage at Numinus’s Vancouver clinic after completing several milestones, including the recruitment of top-notch therapists, physicians, and staff in preparation for participant enrolment and the ultimate analysis of therapy outcomes.20

Numinus (TSX:NUMI) has also made serious headway in its single-arm, open-label compassionate access trial of PRIME for substance use disorders, which is in collaboration with Syreon. The PRIME study, which is currently in the development stage, will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

2. NUMINUS HEALTH:

Having started with a clinic in Vancouver and expanded with Mindspace, Numinus Wellness Inc. (TSX:NUMI) now offers virtual and in-person treatments in 5 clinics across Canada.

Practitioners at Numinus’s Quebec-based clinic currently offer hallucinogenics-assisted psychotherapy, which can be prescribed to address treatment-resistant depression.

Meanwhile, the company’s Vancouver clinic is conducting two compassionate trials that are open to all Canadians:

  • Hallucinogenics-assisted psychotherapy for PTSD, in collaboration with hallucinogenic research and advocacy pioneer MAPS (Multidisciplinary Association for Hallucinogenic Studies)
  • Psilocybin-assisted psychotherapy for substance use disorders

Press Releases

Strong Financial Backing

Numinus Wellness (TSX:NUMI) went public in 2020 after raising an initial $10 million with institutional support from Canaccord Genuity and Eight Capital.

After listing on the TSX-Venture exchange, Numinus Wellness ended 2020 with oversubscribed financing, raising an additional $17 million.

But that’s not all – on March 19, 2021, the company closed a $40 million bought deal financing, pushing the total treasury balance up to nearly $65 million!21

With its two revenue streams, it is obvious why the company ended Q1 2022 with a strong cash position of $53.9 million while clocking in 245% revenue growth year-over-year!22

And it’s little wonder why Numinus (TSX:NUMI) was the Horizons [Hallucinogenics] Stock Index ETF’s (PSYK) top-weighted holding at 9.89% on January 27, 2021, the date of the ETF’s debut launch.23

6 Big Reasons

Why Numinus Wellness Inc. (TSX:NUMI) (OTCQX:NUMIF) is THE Mind-Altering Medicine Stock to Watch in 2022

1

Favorable Regulatory Landscape – The popularity of hallucinogenics is soaring. Both the Canadian and US governments are changing laws and regulations regarding their use. Hallucinogens have already been decriminalized in US cities like Denver, Oakland, Santa Cruz, and Somerville, while psilocybin has been legalized in Oregon for therapeutic purposes. Canada is also well on its way to decriminalizing.

2

Healthcare is Failing Those With Mental Illness – Current statistics say 971 million people worldwide suffer from mental disorders. In Canada, one out of two Canadians is affected by mental health issues by 40. Hallucinogens have shown great promise in treating mental disorders.

3

Massive New Market Opportunity is Being Created – With the addressable market for mental health now surpassing $100 billion, hallucinogens have the opportunity to create a new solution to a growing global problem. In other words, the profit potential for hallucinogenics is huge!

4

The Company Has First Mover Advantage – Numinus Wellness (TSX:NUMI) is the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms! The company also possesses a dealer's license from Health Canada to possess, produce, assemble, sell, import, export, deliver, and distribute acid, hallucinogenics, molly, psilocybin, psilocin, N,N-Dimethyltryptamine, and mescaline.

5

It Has Strong Leadership & R&D Teams – Numinus Wellness Inc. (TSX:NUMI) is led by scientific, medical, and business leaders with expertise in international healthcare research, policy reform, regulatory affairs, capital markets, technology, and government relations. With their extensive market knowledge, they can avoid potential landmines and find the best route to success.

6

The Company Has Gotten Off to a Great Start – Numinus Wellness Inc. (TSX:NUMI) is already generating revenue, and it is the first public company to complete a legal harvest of psilocybe mushrooms. It now has plans to develop its own psilocybin products later this year!

All of these reasons and more are why institutional money is starting to get behind Numinus.

Numinus Wellness Inc.’s (TSX:NUMI) strong financial position, its future development plans, and expected updates from federal governments concerning the legal status and availability of psychoactive treatments all point to Numinus receiving even more positive attention in the future.

Another Factor in Numinus’s Favor – the Increased Attention Being Paid to Mental Health & Substance Abuse

The recent global lockdown brought more attention to mental health and substance abuse, which is not going away once the crisis ends.

Truth is, mental illness has reached crisis proportions and hallucinogens are emerging as a new category of medicine that shows promise.

That’s why governments are easing restrictions and allowing for compassionate use in cases like Numinus Wellness Inc.’s (TSX:NUMI) clinical trials (more on them later).

Plus, there's growing support from scientists who are studying this new class of medicines.

A first of its kind research center at Imperial College in London has been studying how medicines such as acid, psilocybin, N,N-Dimethyltryptamine, and molly impact the brain, and how they may be useful in treating disorders like depression.

As yet another example of the growing interest in hallucinogens, the John Hopkins School of Medicine opened a Center for Hallucinogenic and Consciousness Research in Baltimore in 2019 .

It is studying psilocybin as a treatment for Alzheimer’s disease, PTSD, smoking, anorexia, and depression.

Studies also are planned for substance abuse and post-treatment of Lyme disease. With $17 million in funding from private donors, the facility is the first research center of its kind in the US, and the largest such center in the world.

[BONUS-POPUP id="1"]

Not to be left out, Numinus Wellness Inc. (TSX:NUMI) is also taking a lead role in mental health treatment.

The company is already operating 4 clinics in Vancouver and Montreal and after striking a deal to acquire the Neurology Centre of Toronto (NCT), Numinus plans to create the first centre for excellence in psychoactive neurology. NCT, which is already a fully operational neurology centre with 13 doctors, 8 allied health staff, nurse practitioners and physician assistants, boasted gross revenues of $1 million in 2020.28

Numinus Wellness Inc. (TSX:NUMI) also recently acquired Mindspace - a full-service well-being company that began as psychology clinic with an evidence-based approach to mental health.

Mindspace boasts primarily PhD-level psychotherapists, while delivering therapy both in-person and virtually.

With these developments, Numinus Wellness Inc. (TSX:NUMI) can now offer a full range of therapies. Among them are psilocybin-assisted psychotherapy and compassionate access trials for psilocybin and molly.

Pending approval of the regulatory change, Numinus also intends to support practitioners through Special Access to hallucinogenic-assisted therapies for patients with potentially life-threatening conditions.

Clinics are a critical component of Numinus Wellness' multi-pronged business strategy, as they allow the company to interact directly with clients and build brand awareness. Meanwhile, Numinus continues to innovate, research, and develop new emerging science for the industry.

In the News

Currently, Numinus Wellness Inc. (TSX:NUMI) is undertaking two compassionate access clinical trials for both psilocybin and molly, the first of their kind in Canada.

The psilocybin trial, for example, is an open-label clinical trial evaluating and refining best practices for psilocybin-assisted psychotherapy for people with opioid, alcohol, and stimulant addictions.

It’s truly an enormous marketplace, and Numinus Wellness (TSX:NUMI) has a first-mover advantage thanks to its ability to cultivate and harvest directly, and then develop new formulas for products in clinical trials.

Not only can Numinus create new innovative products, but by having its dealer’s license, the company also has the ability to import, export, possess, test, and distribute molly, psilocybin, psilocin, and N,N-Dimethyltryptamine.

It’s a massive opportunity, and Numinus Wellness Inc. (TSX:NUMI) is the ideal candidate for major medical companies to form partnerships, hire contract research services, or engage in analytical testing services. The company’s diverse, multidisciplinary approach puts Numinus front and center with its unique offerings.

Two more things giving Numinus Wellness Inc. (TSX:NUMI) a market advantage are:

1. Its location in Canada

As part of the Canadian Government's progressive stance on psilocybin and other hallucinogenics used as therapeutics, Canadian companies like Numinus Wellness Inc. (TSX:NUMI) are at the forefront of this new treatment approach.

2. Its Knowledgeable Leadership Team

Numinus Wellness Inc.’s (TSX:NUMI) team consists of a terrific blend of acclaimed scientists, mental health experts, and successful entrepreneurs.

Team members include:

Payton Nyquvest, Co-founder & Chief Executive Officer Executive - 15+ years in Canada/US capital markets, including raises for early MMJ. Raised $100M+ for public and private companies across North America. Former VP and Head of Sales of one of Canada’s largest independent brokerages.
Dr. Evan Wood, MD, PhD Chief Medical Officer - Research leader on addiction medicine and driver of major health policy reform. Contributed to international guidelines on treatment of HIV in substance users; establishment of Canada’s first supervised injecting site and standards of care; legalization of adult MMJ use; and national clinical therapeutic guidelines for multiple substance use disorders. Former Tier 1 Canada Research Chair, UBC Professor of Medicine, founding Executive Director of BC Centre on Substance Use. Published 500+ scientific articles.
Michael Tan, MBA Chief Operations Officer - 20+ years’ operations leadership driving business transformation for global companies, including Indigo, Hudson’s Bay, UPS, and Saks Fifth Avenue. Launched province-wide recreational MMJ operations in BC as founding executive Director of the BC Liquor Distribution Branch-MMJ Division.
John Fong, CPA Chief Financial Officer - 15+ years building global financial operations for private and public companies (TSX-V, NYSE, London AIM, Lima SE), with experience across mining & resources and technology. Led a precious metals company from exploration to commercial production in 3 years, with net income of $100M and operating cash flow of $98M.
8 Investment Highlights

for Numinus Wellness Inc. (TSX:NUMI):

1

Prolific Investors Entering the Market - Peter Thiel, the founder of Paypal and Palantir, has invested in hallucinogenics, along with Kevin O’Leary and Bruce Linton.

2

Regulatory Changes Happening Fast – Just like what happened with MMJ in its infancy, hallucinogenics are gaining momentum as the regulatory policies begin to adapt to the evolving landscape. Canada recently closed its 60-day public commentary period regarding psilocybin and molly, and their statements are imminent.

3

Multiple Revenue Streams - Numinus has a multi-pronged profit strategy that encompasses two different market segments and provides the company with a diversified and synergistic approach to success.

4

Health Canada-Licensed Lab – It’s the first public company with a license to cultivate and harvest psilocybin for research and development. Future products are planned.

5

Strong Financial Footing – It has approximately $65 million in cash in the bank to execute its business milestones.

6

Huge Potential Upside – Numinus has a low market capitalization relative to the total addressable market value ($100 billion). The company was valued at US$97.3 million on February 1, 2022.

7

Seasoned Management & R&D Team – The company has a medical team with over 500+ peer-reviewed publications and a management team with a strong capital markets IQ.

8

Top ETF Holding - Horizons [Hallucinogenic] Stock Index ETF (PSYK), the first Hallucinogenic ETF, listed Numinus Wellness Inc. (TSX:NUMI) as its largest holding at 9.89% on the date of the ETF’s launch on January 27, 2021.

[BONUS-POPUP id="1"]

Please See Disclaimer

[1]https://tinyurl.com/2p8ct3x3 [2]https://tinyurl.com/2ezct2wj [3]New Investor Deck Slide 5 [4]https://tinyurl.com/2p99eczk [5]https://tinyurl.com/yckk7zv2 [6]https://tinyurl.com/2p8ze4u8 [7]Original Investor Deck Slide 7 [8]https://www.google.com/url?q=https://www.sacbee.com/news/politics-government/capitol-alert/article250445971.html&sa=D&source=docs&ust=1643238412250471&usg=AOvVaw2eCF4he5H6-Dk9UiJV9qWf [9]https://tinyurl.com/2p8ct3x3 [10]https://maps.org/about-maps/#history [11]https://www.newswire.ca/news-releases/numinus-announces-key-milestones-in-maps-sponsored-molly-assisted-therapy-for-ptsd-clinical-trial-879526713.html [12]https://tinyurl.com/5ceeapfj [13]https://tinyurl.com/5ceeapfj [14]https://tinyurl.com/mr2e2vyf [15]https://www.newswire.ca/news-releases/numinus-wellness-inc-reports-q1-2022-results-824217004.html [16]https://tinyurl.com/mwzkwkcx [17]https://www.investors.numinus.com/news/news-details/2022/Numinus-Submits-Clinical-Trial-Application-for-Phase-1-Trial-on-Proprietary-Psilocybin-Product/default.aspx [18] https://www.newswire.ca/news-releases/numinus-announces-health-canada-approval-of-maps-sponsored-open-label-study-for-molly-assisted-therapy-for-ptsd-864100377.html [19]https://tinyurl.com/4dhfmhsx [20]https://tinyurl.com/c79yusjy [21]https://www.stockwatch.com/News/Item/Z-C!NUMI-3050672/C/NUMI [22]https://www.newswire.ca/news-releases/numinus-wellness-inc-reports-q1-2022-results-824217004.html [23] https://www.horizonsetfs.com/horizons/media/pdfs/productsheets/PSYK-Product-Sheet.pdf [24]https://mindmed.co/news/press-release/mindmed-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-project-lucy [25]https://compasspathways.com/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression/ [26]https://www.globenewswire.com/news-release/2020/08/18/2079824/0/en/Mydecine-Launches-World-s-First-Natural-Sourced-cGMP-Psilocybin-for-Global-Research-Sales-and-Distribution-Enterprise.html [27]https://www.joplinglobe.com/region/national_business/cybin-granted-dea-schedule-i-manufacturing-license/article_6237bcb6-b54f-5cac-808d-13ead651208f.html [28]https://tinyurl.com/wmh8kyj7

Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Numinus Wellness Inc. Market Jar Media Inc. has or expects to receive from Numinus Wellness Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) two hundred eight thousand two hundred forty-eight USD and seventy five cents for 26 days (19 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on PotStockNews.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on PotStockNews.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Numinus Wellness Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Numinus Wellness Inc.’s industry; (b) market opportunity; (c) Numinus Wellness Inc.’s business plans and strategies; (d) services that Numinus Wellness Inc. intends to offer; (e) Numinus Wellness Inc.’s milestone projections and targets; (f) Numinus Wellness Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Numinus Wellness Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Numinus Wellness Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Numinus Wellness Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Numinus Wellness Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Numinus Wellness Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Numinus Wellness Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Numinus Wellness Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Numinus Wellness Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Numinus Wellness Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Numinus Wellness Inc.’s business operations (e) Numinus Wellness Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Numinus Wellness Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Numinus Wellness Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Numinus Wellness Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Numinus Wellness Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Numinus Wellness Inc. or such entities and are not necessarily indicative of future performance of Numinus Wellness Inc. or such entities.